Determination of Pt–DNA adducts and the sub-cellular distribution of Pt in human cancer cell lines and the leukocytes of cancer patients, following mono- or combination treatments, by inductively-coupled plasma mass spectrometry

NanoSIMS analysis of an isotopically labelled organometallic ruthenium(ii) drug to probe its distribution and state in vitro

“…that the stability/liability of the ligands coordinated to the metal center can be probed via isotopic labelling. The ability to differentiate between the accumulation of a compound on the membrane versus intracellular accumulation in specific organelles illustrates the utility of the NanoSIMS relative to other techniques used to probe metallodrug distribution, such as inductively coupled plasma mass spectrometry and atomic absorption spectroscopy, [22][23][24][25] where such a spatial distinction cannot be made without cell fractionation, a process likely to introduce other distribution artifacts.…”

Oxaliplatin complexes with carnosine and its derivatives: in vitro cytotoxicity, mass spectrometric and computational studies with a focus on complex fragmentation

“…al. [18] we can assume that the majority of the administered drug is found in the cell cytosol. It is thought that the most likely sites for oxaliplatin interaction are the thiol groups of intercellular peptides and proteins.…”

“…Given that there are 1-5 Pt adducts per 10 6 nucleotides in patient white blood cells which represents approximately 10% of the total administered drug. [18] Assuming all nuclear Pt is bound to DNA, representing approximately 10 5 Pt atoms per cell, the majority of the administered drug is available to bind to other ligands such as proteins and peptides within the cell. With a large concentration of proteins per cell, approximately 10 6 -10 7 , [46] many with multiple binding sites, the potential for a wide range of Pt adducts to exist within the cell rather than specific Pt targets is a possible scenario.…”

Analysis of mono-phosphate nucleotides as a potential method for quantification of DNA using high performance liquid chromatography–inductively coupled plasma-mass spectrometry

“…The method presented here is able to distinguish contaminants of the DNA sample by differentiating between retention times. Recently, 31 P, determined by ICP-MS, was used to estimate DNA yields in samples from patients undergoing Pt-based chemotherapy [2]. A robust and more accurate analytical method based on LC-ICP-MS could improve the reliability of such results.…”